MyFinsight
Home
Blog
About
Proceeds from maturities
of...
$99,634K
Proceeds from sales of
available-for-sale securities
$25,040K
Net cash used in
investing activities
$43,683K
(121.63%↑ Y/Y)
Canceled cashflow
$80,991K
Net (decrease)
increase in cash, cash...
-$134,235K
(-588.39%↓ Y/Y)
Canceled cashflow
$43,683K
Non-cash interest
expense on credit...
$15,112K
(-69.02%↓ Y/Y)
Stock-based compensation
$14,872K
(-66.41%↓ Y/Y)
Non-cash interest
expense on liability...
$8,683K
(-54.04%↓ Y/Y)
Accounts receivable
-$6,954K
(-170.66%↓ Y/Y)
Accrued expenses
$6,922K
(-13.00%↓ Y/Y)
Depreciation and
amortization
$6,659K
(-62.04%↓ Y/Y)
Loss on equity method
investment
-$2,471K
Amortization of convertible
notes issuance costs
$766K
Non-cash transfer of
property and equipment to...
$24K
Proceeds from issuance of
common stock-At The...
$27,953K
Dividends paid by variable
interest entity to...
-$3,080K
Proceeds from the
exercises of stock options
$2,617K
(-24.71%↓ Y/Y)
Purchases of
available-for-sale securities
$77,137K
Purchases of property,
plant and equipment
$3,854K
(-74.61%↓ Y/Y)
Net cash (used in)
provided by operating...
-$177,469K
(-211.57%↓ Y/Y)
Canceled cashflow
$62,463K
Net cash provided by
financing activities
-$449K
(-100.64%↓ Y/Y)
Canceled cashflow
$33,650K
Net (loss) income
-$178,921K
(-1378.65%↓ Y/Y)
Deferred revenue
-$30,820K
(-234.12%↓ Y/Y)
Prepaid expenses and
other current assets
$21,527K
(-3.65%↓ Y/Y)
Accounts payable
-$3,093K
(-114.28%↓ Y/Y)
Other
$2,814K
(189.96%↑ Y/Y)
Accretion of
available-for-sale securities...
$1,607K
(-64.64%↓ Y/Y)
Operating lease, net
-$1,133K
(66.84%↑ Y/Y)
Realized gain on
investments
$17K
Repayments of credit
facility
$33,385K
(-83.44%↓ Y/Y)
Payments of issuance
costs of common...
$714K
Back
Back
Cash Flow
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
source: myfinsight.com